Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 14/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23850454 | 0.98 | NAAA (0.51) | NAAAACHEGAAMAPK1HTT | |
| Acetic Acid SCHEMBL4473079 | 0.95 | NAAA (0.49) | NAAAACHEGAAMAPK1HTT | |
| SCHEMBL951710 | 0.87 | GAA (0.50) | NAAAACHEGAAMAPK1HTT | |
| SCHEMBL28229178 | 0.87 | GAA (0.50) | NAAAACHEGAAMAPK1HTT | |
| SCHEMBL28246288 | 0.87 | GAA (0.50) | NAAAACHEGAAMAPK1HTT | |
| SCHEMBL22236153 | 0.85 | NAAA (0.51) | NAAAACHEGAAMAPK1HTT | |
| Bicarbonate SCHEMBL9827045 | 0.85 | GAA (0.48) | NAAAACHEGAAMAPK1HTT | |
| SCHEMBL791466 | 0.85 | MAPK1 (0.48) | NAAAGAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL29842368 | 0.85 | MAPK1 (0.48) | NAAAGAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL31580592 | 0.85 | MAPK1 (0.48) | NAAAGAAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175999-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| CN-101959882-B | Imidazole carbonyl compound | DAIICHI SANKYO CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | NAAA 1596/4885ACHE 474/4885GAA 4060/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | NAAA 624/4885ACHE 2710/4885GAA 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.